Clinical

Chest Pain Choice tool decreases health care utilization


 

Background: Patients who complain of chest pain make up over a quarter of annual hospital admissions, but not all chest pain is attributable to acute coronary syndrome. The one-page CPC document was developed to facilitate joint decision making between low-risk patients and providers regarding the work-up for chest pain.

Study design: Parallel, randomized, controlled trial.

Setting: Six U.S. medical centers.

Synopsis: After reviewing the CPC tool, patients with low cardiac risk who presented to the ED with chest pain were given the option either to be admitted to the hospital for cardiac testing or to not be admitted and instead follow up with their primary care doctor or a cardiologist within 3 days to determine what further cardiac work-up might be warranted.

Upon reviewing data obtained from 898 patient diaries regarding use of health care services, as well as from billing data from the medical centers, the researchers found no statistically significant difference between patients who used the CPC tool and those treated under usual care with regard to hospital readmission rates, length of stay in the ED, repeat ED visits, or clinic visits. However, at the 45-day follow-up mark, those in the CPC group had undergone fewer tests and cardiac imaging studies (decrease of 125.6 tests/100 patients; 95% confidence interval, 29.3-221.6).

Bottom line: Shared decision making between providers and patients with low cardiac risk factors that used the Chest Pain Choice tool decreased some health care utilization without worsening outcomes.

Citation: Schaffer JT et al. Impact of a shared decision-making intervention on health care utilization: A secondary analysis of the Chest Pain Choice multicenter randomized trial. Acad Emerg Med. 2018 Mar;25(3):293-300.

Dr. Maryann T. Ally, Division of Hospital Medicine, UC San Diego Health

Dr. Maryann T. Ally

Dr. Ally is a hospitalist at UC San Diego Health and an assistant clinical professor at the University of California, San Diego.

Recommended Reading

Guidelines to optimize treatment of reduced ejection fraction heart failure
The Hospitalist
Long-acting bronchodilators increase CVD risk in certain COPD patients
The Hospitalist
LAAC in nonvalvular AF provides stroke protection comparable to warfarin
The Hospitalist
Safety of MRI in patients with implantable cardiac devices
The Hospitalist
Kawasaki disease: New info to enhance our index of suspicion
The Hospitalist
DOAC’s edge over warfarin fades with low adherence
The Hospitalist
USPSTF: Don’t add ECG for cardio risk assessment
The Hospitalist
hs-cTnT test tied to fewer reinfarctions but no survival benefit
The Hospitalist
Galectin-3: A new post-MI prognostic biomarker?
The Hospitalist
MI risk prediction after noncardiac surgery simplified
The Hospitalist
   Comments ()